Alexis Ji

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.

Developing simple to use technology to understand complex cellular biology. We are a team of scientists passionate about genomic technologies and how innovative technologies fuel new waves of scientific discoveries and clinical applications. Our group consists of reputable inventors in both academia and industry, as well as seasoned biotech entrepreneurs and executives with a strong track record in bringing genomic technologies from concept to commercialization.

In an era of ever-increasing cost and skills required to do complex diagnostics tests, Enumerix is developing a next-generation genomics platform to make high resolution biology simple, fast, and affordable. Our goal is to reduce the cost of high resolution tests by at least 10 times to enable access to a broader patient population. We believe our team is poised to accomplish this. We are a group of seasoned biotech and innovative entrepreneurs, engineers, and scientists with a proven track record of advancing the field of genomics from innovation to commercial success. We have pioneered DNA microarrays, non-invasive prenatal screening using next generation sequencing (NGS), and high-throughput single-cell NGS, and together the founding team holds over 60 granted patents.

Walking Fish has created a broad B cell platform for oncology, regenerative medicine, autoimmune disease, and recombinant antibody production. As a leader in B cell engineering, Walking Fish has made critical advances in engineering technologies and has a deep understanding about B cell biology. The WFT team includes experienced researchers excited about our new approach to the treatment of severe diseases.

Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies.

SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could change the way people think about cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and in immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases.

NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, by ensuring high cell viability required to advance cell-based research. We develop and deliver microfluidic based solutions that are affordable, compact, and easy-to-use. Our expanding portfolio of instruments and consumables enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, and industrial chemicals, scientists use our synthetic genes, oligo pools, biopharma services, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead. Twitter @TwistBioscience Facebook facebook.com/TwistBioscience YouTube youtube.com/TwistBioscience #WeMakeDNA

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.

Developing simple to use technology to understand complex cellular biology. We are a team of scientists passionate about genomic technologies and how innovative technologies fuel new waves of scientific discoveries and clinical applications. Our group consists of reputable inventors in both academia and industry, as well as seasoned biotech entrepreneurs and executives with a strong track record in bringing genomic technologies from concept to commercialization.

In an era of ever-increasing cost and skills required to do complex diagnostics tests, Enumerix is developing a next-generation genomics platform to make high resolution biology simple, fast, and affordable. Our goal is to reduce the cost of high resolution tests by at least 10 times to enable access to a broader patient population. We believe our team is poised to accomplish this. We are a group of seasoned biotech and innovative entrepreneurs, engineers, and scientists with a proven track record of advancing the field of genomics from innovation to commercial success. We have pioneered DNA microarrays, non-invasive prenatal screening using next generation sequencing (NGS), and high-throughput single-cell NGS, and together the founding team holds over 60 granted patents.

Primer Ventures is a life science venture capital fund based in Silicon Valley, focusing on early-stage (Series pre-A, A, B) investments in the fields of life science tools, innovative therapeutics, and molecular diagnostics. Our mission is to empower visionary entrepreneurs to transform advanced science and technology into groundbreaking products, therapies and services. We constantly seek high-potential ventures as investment targets and are eager to engage with investors, entrepreneurs, startups and strategics.

Walking Fish has created a broad B cell platform for oncology, regenerative medicine, autoimmune disease, and recombinant antibody production. As a leader in B cell engineering, Walking Fish has made critical advances in engineering technologies and has a deep understanding about B cell biology. The WFT team includes experienced researchers excited about our new approach to the treatment of severe diseases.